Objective: Some commentators argue that informed consent for clinical research should be an on-going process, which begins, rather than ends, with participants' initial consent. Lacking, however, are empirical data on whether there is a need for 'ongoing consent'.
Introduction
Informed consent has been recognized as an ethical requirement for clinical research since at least the Nuremberg Code of 1947 [1, 2] . Standard practice implements this requirement in four steps: explaining the study to potential participants, answering any questions, obtaining their informed consent, and providing them with a copy of the consent form [3, 4] . Yet, some commentators argue that this standard consent process is not sufficient to fully protect research participants [5, 6] . They argue that informed consent for clinical research should include a process to keep participants informed over time about aspects of the study relevant to their on-going participation [7] [8] [9] [10] [11] [12] [13] . standard consent process is sufficient for clinical research [16] . Specifically, is the standard informed consent process sufficient to keep research participants informed over time about aspects of the study relevant to their on-going participation? To begin to address this question, the present study evaluated the understanding and desire for information of individuals who were participating in a longer-term clinical trial.
Methods

Participants
The present data were collected from two selfadministered surveys of individuals participating in the Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT) . ESPRITwas an open-label trial which compared antiretroviral therapy and interleukin-2 (IL-2) to antiretroviral therapy alone in individuals infected with HIV [17, 18] . The study enrolled 4150 HIV-positive men and women, 18 years or older, with a minimum baseline CD4 cell count of 300 cells/ml in 25 countries, mostly in Europe. Enrolled participants returned to the clinic every 4 months for medical evaluation and collection of blood samples. Participants randomized to IL-2 received three cycles of subcutaneous IL-2 during 5 consecutive days every 8 weeks, and then additional cycles based on their CD4 þ cell count. Median follow-up in ESPRIT was 6.8 years.
Concern has been expressed that research participants in developing countries are less likely to provide valid informed consent. With this in mind, the present survey focused on the three developing countries that participated in ESPRIT: Argentina, Brazil, and Thailand.
ESPRIT consent procedures ESPRIT thoroughly implemented the standard consent process used in clinical research. In Argentina and Brazil, potential participants had an initial meeting with an ESPRIT researcher who explained the entire study, went over the consent form, and answered questions. In Thailand, the initial meeting involved a 2-h group discussion led by research nurses in which the consent form was read page by page, and discussed with the group. In all three countries individuals were then given time to consider the study and discuss it with others, including family and clinicians. At a second meeting, potential participants met with a researcher who again explained the study and answered any questions prior to inviting interested individuals to sign the consent form.
The consent form was 2600 words long and described all the essential elements of informed consent. With respect to the possibility of withdrawal from the study, the consent form stated: 'Your participation is entirely voluntary. You may decide not to take part or to withdraw from the study at any time without losing the benefits of your routine medical care'. With respect to the post-trial provision of IL-2, the consent form stated: 'If the research finds that IL-2 is well tolerated and effective for HIV patients, and you and your doctor decide that you want to take it, the company supplying IL-2 during this study will provide it to you until it is approved for use for HIV infection'. All participants were provided with a copy of the consent form. Enrolled participants also received several letters during the study which informed them of new information regarding the side effects of IL-2 and extension of the study.
Surveys
ESPRIT participants in Argentina, Brazil, and Thailand were invited to participate in two self-administered surveys, based on the availability of clinic staff. The baseline survey was completed just after consent, but prior to randomization. Individuals were invited to participate in the follow-up survey after they had been enrolled in ESPRIT for 2-3 years, whether or not they had completed the baseline survey. Completed surveys were mailed to the statistical and data management center for ESPRIT at the University of Minnesota; clinical research staff did not have access to the completed surveys.
The surveys were developed in nine steps: literature review; draft survey development; review and revision by survey professionals; cognitive, behavioral, and reliability pretesting with ESPRIT participants in the US; revision; translation into Portuguese, Spanish, and Thai; backtranslation into English and revision; translation into Portuguese, Spanish, and Thai; and review of the translated surveys by native investigators.
The two surveys used primarily close-ended questions in four domains: understanding of ESPRIT; motivations for participation; impact of participation; and compliance with study requirements. The present study reports findings from the first domain. Responses in this domain were examined to assess participants' understanding of IL-2 and ESPRIT, whether they wanted more information, whether they had asked any questions during the study, and whether they felt any pressure to remain in the study (see Tables 1 and 2 for the verbatim questions).
Statistical analysis
The baseline characteristics of respondents were compared using chi-squared analysis for categorical data and the Kruskal-Wallis test for continuous data. For questions with ordinal responses on the follow-up questionnaire, a proportional odds model was used to assess the effect of treatment group after adjustment for sex, age, race, country, and participation in the baseline survey. Logistic regression was used for binary responses. For respondents who completed both the baseline and follow-up surveys, responses were compared by time period, with and without a term for treatment group by time interaction, using generalized models appropriate for multinomial paired data. The interaction in these models assesses whether the difference in responses between baseline and follow-up varies by treatment group.
Approvals
The study was approved by the Dr Virgilioss G. Foglia Ethics Committee, Buenos Aires, Argentina; the Emilio Ribas Institute of Infectious Disease Ethics Committee, Sao Paulo, Brazil; the Ethics Committee of the Faculty of Medicine, Chulalongkorn Hospital, Bangkok, Thailand; and the institutional review board at the National Institute of Allergy and Infectious Diseases, Bethesda, Maryland. All respondents provided informed consent before completing the surveys.
Results
Respondents
The participating sites in the three countries enrolled 854 participants in ESPRIT. The baseline survey was completed by 318 participants (37.2%) just after consent, but prior to randomization ( Fig. 1 ). Whereas formal response rates were not collected for the baseline survey, investigators report that only a few invited participants declined to complete the baseline survey. Of the 854 ESPRIT participants at the sites in the three countries, 595 (69.7%) were invited to complete the follow-up survey, and 582 (response rate ¼ 97.8%) did so. Of these 582 participants, 292 were receiving IL-2 and 290 were in the control arm; 253 of those who completed the followup survey had also completed the baseline survey.
Respondents to the follow-up survey had been enrolled in ESPRIT for a mean of 2.5 years. Nearly 70% were men, mean age was 37.6, approximately eight in 10 were employed, and approximately 40% had attended college or university ( Table 3 ). The characteristics of ESPRIT participants who did not complete the follow-up survey, ESPRIT participants who completed both the follow-up and baseline surveys, and ESPRIT participants who completed the follow-up survey only were similar (Table 4 ).
Are participants informed at follow-up?
Respondents to the follow-up survey reported being significantly less informed than respondents to the baseline survey. This was evident in all those who completed the follow-up survey ( Table 5 ) and also when the analysis was restricted to those who completed the baseline and follow-up surveys ( Table 6 ).
With respect to the possibility of withdrawal, 2.7% at baseline but 38.5% at follow-up (IL-2 35.1%; control 41.9%) reported being 'not at all' informed. With respect to the possibility of receiving IL-2 after the study, 5.8% of those at baseline but 38.0% of those at follow-up (IL-2 34.4%; control 41.9%) reported being 'not at all' informed ( Table 5 ). Not surprisingly, respondents in the IL-2 arm were significantly more likely to report being well informed at follow-up about IL-2 ( Table 6 ).
Wanting information
Of respondents to the follow-up survey, 71.1% (67.7% IL-2; 74.5% control) responded 'yes' to the question: 'At present, would you like any additional information about the ESPRIT study'. Of these, 27.1% (31.7% IL-2; 23.0% control) wanted more information about the possibility of withdrawal, 61.4% (66.1% IL-2; 57.1% control) wanted more information about the possibility of receiving IL-2 after ESPRIT ended, and 72.6% (73.9% IL-2; 71.4% control) wanted to know when they would learn about study results. Respondents in the IL-2 arm were significantly more likely to want more information about the possibility of withdrawing from ESPRIT (P ¼.029).
Obtaining information
Sixty-five percent of respondents to the follow-up survey (61.6% IL-2; 67.8% control) reported still having a copy of the consent form; another 14% (15.1% IL-2; 13.0% 3. The common side effects of IL-2. 4. The potential medical benefits of IL-2. 5. Whether the ESPRIT sponsors will provide IL-2 to ESPRIT participants after the study ends. 6. The possibility of withdrawing from the ESPRIT study.
Answer choices were: I wish I had received a lot more information; I wish I had received a little more information; I did not need more information. B. Retaining Consent Form 1. Do you still have a copy of the ESPRIT consent form?
Answer choices were: Yes; No (these respondents were instructed to skip the next question); Don't Know (these respondents were instructed to skip the next question). 2. Since the time you signed the ESPRIT consent form, how many times have you looked back at it?
Answer choices were: Never; 1-2 times; 3-5 times; 6-10 times; More than 10 times. C. Asking Questions 1. Since you began participating, have you ever asked the ESPRIT research team for any additional information about the study?
Answer choices were: Yes; No (these respondents were instructed to skip the next question). 2. Why haven't you asked the ESPRIT research team for any additional information about the study? (Mark ALL that apply).
Answer choices were: I didn't want any additional information; I didn't know who to ask; I didn't want to look foolish; I didn't want to be removed from the study; I didn't have an opportunity to ask; Other:
Please specify (open-ended response). D. Obtaining Information from Outside Sources 1. Since you began participating in the ESPRIT study, have you received information about HIV treatments from sources other than the ESPRIT research team? Answer choices were: Yes; No (these respondents were instructed to skip the following 3 questions).
What was the most useful source of information?
Answer 
Discussion
The present data provide the first empirical evaluation of which we are aware on whether the standard consent process used in clinical research is sufficient to keep participants informed over time. The primary finding is that the standard consent process did not keep participants of ESPRIT in Argentina, Brazil, and Thailand informed about aspects of the study central to their on-going participation. Most importantly, at follow-up, almost 4 in 10 respondents reported being 'not at all' informed about their right to withdrawal, and almost 4 in 10 reported being 'not at all' informed about the possibility of receiving the experimental treatment after study completion.
These findings are striking given the context in which they were obtained. ESPRIT's implementation of the standard consent process was comprehensive and in-depth. The effectiveness of this process was assessed in a separate empirical study that evaluated the actual understanding of ESPRIT participants in Thailand [19] . This testing found that, immediately following the initial consent process, participants in Thailand were well informed.
The fact that ESPRIT thoroughly implemented the standard consent process, and ESPRIT participants were well informed at enrollment, suggest that the present findings provide an assessment of the standard consent process under a best case scenario. In particular, it seems extremely unlikely that the present participants' desire for more information traces to their having undergone a suboptimal implementation of the standard consent process at baseline. Instead, these findings suggest that the standard consent process may not be sufficient to protect fully the participants of clinical trials. This conclusion provides empirical support for the claim that longer-term clinical trials should consider including a process to ensure that participants remain informed over time about aspects of the study relevant to their on-going participation, such as the right to withdraw.
It is important to distinguish what has been called 'ongoing consent' from initial consent and re-consent. Initial consent is designed to provide a comprehensive explanation so potential participants can decide whether to enroll in a given study. Re-consent is designed to provide enrolled participants with all the information they need to decide whether to continue to participate given significant changes, such as identification of serious new risks [20] On-going consent, in contrast, is intended to keep participants aware of information relevant to their continued participation. On-going consent occurs subsequent to participants' initial enrollment, and in settings in which no substantial changes have occurred to the study that would warrant obtaining their re-consent. This suggests that on-going consent need not use a consent form nor obtain participants' signature. In addition, a good deal of the information needed for initial consent is not germane to on-going consent. Hence, on-going consent can be much briefer than initial consent, and should cover a much narrower range of information.
For example, at the time of the follow-up survey, respondents in the control arm did not feel informed about IL-2. Whereas this information was important to initial consent, it seems unimportant to the on-going participation of individuals who have been randomized to the control arm. In contrast, awareness of the risks and potential benefits of IL-2 could be crucial to these individuals' options following the study. This possibility suggests that on-going consent might include an exit interview at the completion of individuals' participation to provide them with information relevant to their next steps.
On-going consent could be implemented by incorporating into clinical trials periodic and informal discussions. In particular, investigators might briefly discuss upcoming aspects of the study; any changes to participants' circumstances or the study; the importance of the study; the importance of continued participation; and participants' right to withdraw. A process of on-going consent would provide research participants an explicit opportunity to ask questions. This opportunity seems important given the present findings that almost two in three respondents wanted more information, yet over half of these participants had not asked any questions, often because they did not know whom to ask or felt that they did not have an opportunity to ask questions.
The content of the on-going consent meetings should be tailored to the circumstances. What information needs to be highlighted will vary depending on the specific study and participants' point in the study. The process of ongoing consent also should be sensitive to the cultural context. For example, the best approach to providing participants sufficient opportunity to ask questions likely will vary across cultures and countries.
Almost half of the respondents to the follow-up survey had obtained information from outside sources. A few reported that this information conflicted with what the research team had told them, and made them less enthusiastic about participation. While this effect may be especially prominent in research on HIV, for which there are many sources of information, inclusion of a process of on-going consent would provide all investigators with an opportunity to address the possibility of participants receiving inaccurate information.
Respondents who had completed the baseline survey reported being significantly better informed at follow-up, 2-3 years later. Whereas it is unclear what explains this finding, future research might evaluate whether it is possible to supplement the initial consent process in ways that help participants retain relevant information over time.
Some respondents reported feeling pressure from the team to remain enrolled. This finding, while important, should be interpreted with caution. Reports of 'pressure' may reflect a range of experiences, not all of them problematic. Reminding participants of the importance of their participation and even encouraging them to continue can be appropriate provided it is done respectfully and they are assured of their right to withdraw. The fact that some respondents felt pressure 112 AIDS 2011, Vol 25 No 1 to continue to participate from their family/close friends or personal doctor suggests investigators also should be cognizant of other potential sources of pressure.
The present findings are subject to four important limitations. First, the findings are based on self-reports. Whereas individuals' perceptions may not always track how well informed they in fact are, the present respondents' reports of being well informed at baseline correlate with data showing that ESPRIT participants in Thailand were well informed at initial consent [19] . Second, the present data were collected in three countries from sites of a single study for HIV disease. Results may differ for other diseases, and in other places. Third, the right to withdraw [21] and post-trial provision of experimental treatments can be difficult concepts to understand. However, the consent form for ESPRIT seemed to explain both items well. Fourth, the present data do not evaluate the impact on clinical research trials of incorporating a process of on-going consent. Before on-going consent is endorsed generally, pilot testing should be conducted to evaluate its feasibility, cost, and impact on clinical trials.
